eClinical Technology and Industy News

Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine Showing Protection from SARS-CoV-2 Challenge after a Single Dose

Excerpt from the Press Release:

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the release of preclinical data in nonhuman primates (NHPs) of the company’s intranasal recombinant live attenuated COVID-19 vaccine (MV-014-212). The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines. Furthermore, the data show that MV-014-212 stimulates mucosal (nasal IgA) antibodies in the upper respiratory tract, the major infection route for SARS-CoV-2, and systemic (serum neutralizing and binding IgG) antibodies. Meissa also announced that the company has enrolled and dosed SARS-CoV-2 seronegative and seropositive adult participants in all dosage groups of a Phase 1 clinical trial of MV-014-212 (ClinicalTrials.gov identifier: NCT04798001). Interim analysis of the trial data is expected later this year.

“Many scientists and public health officials think SARS-CoV-2 is becoming endemic, and we believe Meissa’s intranasal COVID-19 vaccine can contribute to global control of the disease and virus spread,” said Martin Moore, Ph.D., CEO and Cofounder of Meissa Vaccines. “The data suggest a single, adjuvant-free, needle-free intranasal dose of MV-014-212 may provide broad immunity to protect against infection by SARS-CoV-2 and its variants.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives